Pfizer to end development of experimental obesity pill due to elevated liver enzymes
Pavlo Gonchar | Lightrocket | Getty ImagesPfizer on Monday said it would stop developing its experimental obesity and diabetes pill, lotiglipron, due to elevated liver enzymes in patients who took the drug once a day in mid-stage clinical…